Disturbance of redox status enhances radiosensitivity of hepatocellular carcinoma

American Journal of Cancer Research

Volumn 5, Issue 4, 2015, Pages 1368-1381

  Sun, Chao ^a,b,c   Wang, Zhen Hua ^d   Liu, Xiong Xiong ^a,b,c   Yang, Li Na ^e   Wang, Yali ^e   Liu, Yang ^a,b,c   Mao, Ai Hong ^a,b,c   Liu, Yuan Yuan ^a,b,c   Zhou, Xin ^a,b,c   Di, Cui Xia ^a,b,c   Gan, Lu ^a,b,c   Zhang, Hong ^a,b,c  

^a INSTITUTE OF MODERN PHYSICS   (China)

^b INSTITUTE OF GEOLOGY AND GEOPHYSICS   (China)

^c Key Laboratory of Heavy Ion Radiation Medicine of Gansu Province   (China)

^d YANTAI UNIVERSITY   (China)

^e LANZHOU UNIVERSITY   (China)

Author keywords

Isoliquiritigenin; Keap1 Nrf 2; Radiosensitization; Redox state; ROS

Indexed keywords

GAMMA HISTONE H2AX; HISTONE H2AX; ISOLIQUIRITIGENIN; KELCH LIKE ECH ASSOCIATED PROTEIN 1; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CELL PROTECTION; CLONOGENESIS; CONTROLLED STUDY; DNA DAMAGE; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG MECHANISM; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MALE; MOUSE; NONHUMAN; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN TRANSPORT; RADIOSENSITIVITY; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; UBIQUITINATION; X IRRADIATION;

EID: 85006219352     PISSN: None     EISSN: 21566976     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Zhao YJ, Ju Q and Li GC. Tumor markers for hepatocellular carcinoma. Mol Clin Oncol 2013; 1: 593-598.
2. Venook AP, Papandreou C, Furuse J and de Guevara LL. The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective. Oncologist 2010; 4: 5-13.
3. Llovet JM, Burroughs A and Bruix J. Hepa- tocellular carcinoma. Lancet 2003; 362: 1907-17.
4. Bütof R, Dubrovska A and Baumann M. Clinical perspectives of cancer stem cell research in radiation oncology. Radiother Oncol 2013; 108: 388-96.
5. Peitzsch C, Kurth I, Kunz-Schughart L, Baumann M and Dubrovska A. Discovery of the cancer stem cell related determinants of radioresistance. Radiother Oncol 2013; 108: 378-87.
6. Borek C. Antioxidants and radiation therapy. J Nutr 2004; 34: 3207-3209.
7. Skvortsova I. Oxidative damage and cutaneous reactions during radiotherapy in combination with cetuximab. Radiother Oncol 2009; 90: 281-2.
8. Malorni W and Pietraforte D. Focusing at the double edged sword of redox imbalance: signals for cell survival or for cell death? Antioxid Redox Signal 2013; 19: 559-71.
9. Tominaga H, Kodama S, Matsuda N, Suzuki K and Watanabe M. Involvement of reactive oxygen species (ROS) in the induction of genetic instability by radiation. J Radiat Res 2004; 45: 181-8.
10. Greenberger JS, Kagan VE, Pearce L, Boriseniao G, Tyurina Y and Epperly MW. Modulation of redox signal transduction pathways in the treatment of cancer. Antioxid Redox Signal 2001; 3: 347-59.
11. Acharya A, Das I, Chandhok D and Saha T. Redox regulation in cancer: a double-edged sword with therapeutic potential. Oxid Med Cell Longev 2010; 3: 23-34.
12. Qu Y, Wang J, Ray PS, Guo H, Huang J, Shin-Sim M, Bukoye BA, Liu B, Lee AV, Lin X, Huang P, Martens JW, Giuliano AE, Zhang N, Cheng NH and Cui X. Thioredoxin-like 2 regulates human cancer cell growth and metastasis via redox homeostasis and NF-κB signaling. J Clin Invest 2011; 121: 212-25.
13. Natsuizaka M, Kinugasa H, Kagawa S, Whelan KA, Naganuma S, Subramanian H, Chang S, Nakagawa KJ, Rustgi NL, Kita Y, Natsugoe S, Basu D, Gimotty PA, Klein-Szanto AJ, Diehl JA and Nakagawa H. IGFBP3 promotes esophageal cancer growth by suppressing oxidative stress in hypoxic tumor microenvironment. Am J Cancer Res 2014; 15: 29-41.
14. Yang G, Zhao K, Ju Y, Mani S, Cao Q, Puukila S, Khaper N, Wu L and Wang R. Hydrogen sulfide protects against cellular senescence via S- sulfhydration of Keap1 and activation of Nrf2. Antioxid Redox Signal 2013; 18: 1906-19.
15. Baird L, Llères D, Swift S and Dinkova-Kostova AT. Regulatory flexibility in the Nrf2-mediated stress response is conferred by conformational cycling of the Keap1-Nrf2 protein complex. Proc Natl Acad Sci U S A 2013; 110: 15259-64.
16. Masutani H, Otsuki R, Yamaguchi Y, Takenaka M, Kanoh N, Takatera K, Kunimoto Y and Yodoi J. Fragrant unsaturated aldehydes elicit activation of the Keap1/Nrf2 system leading to the upregulation of thioredoxin expression and protection against oxidative stress. Antioxid Redox Signal 2009; 11: 949-62.
17. Yu S, Khor TO, Cheung KL, Li W, Wu TY, Huang Y, Foster BA, Kan YW and Kong AN. Nrf2 expression is regulated by epigenetic mechanisms in prostate cancer of TRAMP mice. PLoS One 2010; 5: 8579.
18. Jaramillo MC and Zhang DD. The emerging role of the Nrf2-Keap1 signaling pathway in cancer. Genes Dev 2013; 27: 2179-91.
19. Akhdar H, Loyer P, Rauch C, Corlu A, Guillouzo A and Morel F. Involvement of Nrf2 activation in resistance to 5-fluorouracil in human colon cancer HT-29 cells. Eur J Cancer 2009; 12: 2219-27.
20. Zhou S, Ye W, Shao Q, Zhang M and Liang J. Nrf2 is a potential therapeutic target in radioresistance in human cancer. Crit Rev Oncol Hematol 2013; 88: 706-15.
21. Lee S, Lim MJ, Kim MH, Yu CH, Yun YS, Ahn J and Song JY. An effective strategy for increasing the radiosensitivity of Human lung Cancer cells by blocking Nrf2-dependent antioxidant responses. Free Radic Biol Med 2012; 53: 807-16.
22. Gaur R, Yadav KS, Verma RK, Yadav NP and Bhakuni RS. In vivo anti-diabetic activity of derivatives of isoliquiritigenin and liquiritigenin. Phytomedicine 2014; 21: 415-22.
23. Chen H, Zhang B, Yuan X, Yao Y, Zhao H, Sun X and Zheng Q. Isoliquiritigenin-induced effects on Nrf2 mediated antioxidant defence in the HL-60 cell monocytic differentiation. Cell Biol Int 2013; 37: 1215-24.
24. Yamamoto S, Aizu E, Jiang H, Nakadate T, Kiyoto I, Wang JC and Kato R. The potent anti-tumor-promoting agent isoliquiritigenin. Carci- nogenesis 1991; 12: 317-23.
25. Hajirahimkhan A, Simmler C, Yuan Y, Anderson JR, Chen SN, Nikolic D, Dietz BM, Pauli GF, van Breemen RB and Bolton JL. Evaluation of estrogenic activity of licorice species in comparison with hops used in botanicals for menopausal symptoms. PLoS One 2013; 8: e67947.
26. Yu SM and Kuo SC. Vasorelaxant effect of isoliquiritigenin, a novel soluble guanylate cyclase activator, in rat aorta. Br J Pharmacol 1995; 114: 1587-94.
27. Sun C, Zhang H, Ma XF, Zhou X, Gan L, Liu YY and Wang ZH. Isoliquiritigenin enhances radiosensitivity of HepG2 cells via disturbance of redox status. Cell Biochem Biophys 2013; 65: 433-44.
28. Schiettecatte J, De Schepper J, Velkeniers B, Smitz J and Van Steirteghem A. Rapid detection of macroprolactin in the form of prolactin-immunoglobulin G complexes by immunoprecipitation with anti-human IgG-agarose. Clin Chem Lab Med 2001; 39: 1244-8.
29. Figarella K, Uzcategui NL, Beck A, Schoenfeld C, Kubata BK, Lang F and Duszenko M. Pros- taglandin-induced programmed cell death in Trypanosoma brucei involves oxidative stress. Cell Death Differ 2006; 13: 1802-14.
30. Sun C, Wang Z, Liu Y, Liu Y, Li H, Di C, Wu Z, Gan L and Zhang H. Carbon ion beams induce hepatoma cell death by NADPH oxidase-mediated mitochondrial damage. J Cell Physiol 2014; 229: 100-7.
31. Devling TW, Lindsay CD, McLellan LI, McMahon M and Hayes JD. Utility of siRNA against Keap1 as a strategy to stimulate a cancer chemopreventive phenotype. Proc Natl Acad Sci U S A 2005; 102: 7280-7285.
32. Liu X, Sun C, Jin XD, Li P, Ye F, Zhao T, Gong L and Li Q. Genistein Enhances the Radiosen- sitivity of Breast Cancer Cells via G2/M Arrest. Molecules 2013; 18: 13200-13217.
33. Huang CF, Zhang L, Ma SR, Zhao ZL, Wang WM, He KF, Zhao YF, Zhang WF, Liu B and Sun ZJ. Clinical significance of Keap1 and Nrf2 in oral squamous cell carcinoma. PLoS One 2013; 8: e83479.
34. Ren D, Villeneuve NF, Jiang T, Wu T, Lau A, Toppin HA and Zhang DD. Brusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated defense mechanism. Proc Natl Acad Sci U S A 2011; 108: 1433-8.
35. Vandersickel V, Depuydt J, Van Bockstaele B, Perletti G, Philippe J, Thierens H and Vral A. Early increase of radiation-induced ?H2AX foci in a human Ku70/80 knockdown cell line characterized by an enhanced radiosensitivity. J Radiat Res 2010; 51: 633-41.
36. Wong CM, Bansal G, Pavlickova L, Marcocci L and Suzuki YJ. Reactive oxygen species and antioxidants in pulmonary hypertension. An- tioxid Redox Signal 2013; 18: 1789-96.
37. Diehn M, Cho RW, Lobo NA, Kalisky T, Dorie MJ, Kulp AN, Qian D, Lam JS, Ailles LE, Wong M, Joshua B, Kaplan MJ, Wapnir I, Dirbas FM, Somlo G, Garberoglio C, Paz B, Shen J, Lau SK, Quake SR, Brown JM, Weissman I L and Clarke MF. Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 2009; 458: 780-783.
38. Gao MC, Jia XD, Wu QF, Cheng Y, Chen FR and Zhang J. Silencing Prx1 and/or Prx5 sensitizes human esophageal cancer cells to ionizing radiation and increases apoptosis via intracellular ROS accumulation. Acta Pharmacol Sin 2011; 32: 528-36.
39. Vaya J, Belinky PA and Aviram M. Antioxidant constituents from licorice roots: isolation, structure elucidation and antioxidative capacity toward LDL oxidation. Free Radic Biol Med 1997; 23: 302-13.
40. Watjen W, Michels G, Steffan B, Niering P, Chovolou Y, Kampkotter A, Tran-Thi QH, Proksch P and Kahl R. Low concentrations of flavonoids are protective in rat H4IIE cells whereas highconcentrations cause DNA damage and apoptosis. J Nutr 2005; 135: 525-31.
41. De Marchi U, Biasutto L, Garbisa S, Toninello A and Zoratti M. Quercetin can act either as an inhibitor or an inducer of the mitochondrial permeability transition pore: A demonstration of the ambivalent redox character of polyphenols. Biochim Biophys Acta 2009; 1787: 1425-32.
42. Robaszkiewicz A, Balcerczyk A and Bartosz G. Antioxidative and prooxidative effects of quercetin on A549 cells. Cell Biol Int 2007; 31: 1245-50.
43. Galati G, Lin A, Sultan AM and O'Brien PJ. Cellular and in vivo hepatotoxicity caused by green tea phenolic acids and catechins. Free Radic Biol Med 2006; 40: 570-80.
44. Bouayed J and Bohn T. Exogenous antioxidants-Double-edged swords in cellular redox state: Health beneficial effects at physiologic doses versus deleterious effects at high doses. Oxid Med Cell Longev 2010; 3: 228-237.
45. Gaspar J, Rodrigues A, Laires A, Silva F, Costa S, Monteiro MJ, Monteiro C and Rueff J. On the mechanisms of genotoxicity and metabolism of quercetin. Mutagenesis 1994; 9: 445-9.
46. Metodiewa D, Jaiswal AK, Cenas N, Dickancaite E and Segura-Aguilar J. Quercetin may act as a cytotoxic prooxidant after its metabolic activation to semiquinone and quinoidal product. Free Radic Biol Med 1999; 26: 107-16.
47. Galati G and O'Brien PJ. Potential toxicity of flavonoids and other dietary phenolics: significance for their chemopreventive and anticancer properties. Free Radic Biol Med 2004; 37: 287-303.
48. Kitano H. Cancer as a robust system: implications for anticancer therapy. Nat Rev Cancer 2004; 4: 227-35.
49. McDonald JT, Kim K, Norris AJ, Vlashi E, Phillips TM, Lagadec C, Della Donna L, Ratikan J, Szelag H, Hlatky L and McBride WH. Ionizing radiation activates the Nrf2 antioxidant response. Cancer Res 2010; 70: 8886-95.
50. D'Andrea GM. Use of antioxidants during chemotherapy and radiotherapy should be avoided. CA Cancer J Clin 2005; 55: 319-21.
51. Lawenda BD, Kelly KM, Ladas EJ, Sagar SM, Vickers A and Blumberg JB. Should supplemental antioxidant administration be avoided during chemotherapy and radiation therapy? J Natl Cancer Inst 2008; 100: 773-83.
52. Moss RW. Do antioxidants interfere with radiation therapy for cancer? Integr Cancer Ther 2007; 6: 281-92.
53. Prasad KN, Cole WC, Kumar B and Che Prasad K. Pros and cons of antioxidant use during radiation therapy. Cancer Treat Rev 2002; 28: 79-91.
54. Simone CB 2nd, Simone NL, Simone V and Simone CB. Antioxidants and other nutrients do not interfere with chemotherapy or radiation therapy and can increase kill and increase survival, part 1. Altern Ther Health Med 2007; 13: 22-8; part 2. Altern Ther Health Med 2007; 13: 40-7.